Actavis acquires bulk drugs unit of Sanmar Speciality

March 2007
Chemical Business;Mar2007, Vol. 21 Issue 3, p78
Trade Publication
The article reports that Actavis has taken over the bulk drugs division of Chennai, India-based Sanmar Specialty Chemicals Ltd. In December 2006, Actavis had taken over Gradix Pharmaceuticals, a tablets manufacturer also in Chennai. With the acquisition of Sanmar, Actavis had not only captured the entire value chain but has also acquired 25 active pharmaceutical ingredients. Actavis has marketing tie-ups with several Indian companies.


Related Articles

  • pharmaceuticals & fine chemicals.  // Chemical Week;1/3/2007, Vol. 169 Issue 1, p31 

    The article presents updates on companies in the industry of pharmaceuticals and fine chemicals. Actavis Group has acquired a manufacturing plant from Grandix Pharmaceuticals. Lonza has agreed to license its glutamine synthetase expression system and GS-CHO protein free system to Roche for the...

  • Full steam ahead for Actavis in generics.  // Chemical Market Reporter;7/17/2006, Vol. 270 Issue 2, p24 

    The article announces that Iceland-based Actavis is pushing through with its generic pharmaceuticals business in its attempt to attain a leading position in the worldwide generic drug industry. Actavis now sells dantrolene and isradipine in the United States. It also markets amantadine,...

  • SSCL to expand outsourcing work. Tong, Alfred // Asian Chemical News;4/19/2004, Vol. 10 Issue 442, p8 

    Reports on the plan of Sanmar Specialty Chemicals Ltd (SSCL) to increase its outsourcing work for U.S. and European pharmaceutical companies in 2004. Businesses of SSCL; Services offered by SSCL; Information on Bangalore Genei, a subsidiary of SSCL.

  • pharmaceuticals & fine chemicals.  // Chemical Week;10/26/2005, Vol. 167 Issue 35, p34 

    Presents an update on the pharmaceutical industry as of October 26, 2005. Purchase of the generic drugs operations of Alpharma by generic drugs firm Actavis Group; Decision of biotechnology manufacturer Progenitor Cell Therapy to manufacture Cellerant Therapeutics' stem cell drug candidate CLT-001.

  • Actavis to Build Three Plants in India; Opens Laboratories. Ramesh, Deepti // Chemical Week;11/3/2008, Vol. 170 Issue 34, p31 

    The article reports on the announcement by generics pharmaceutical manufacturer Actavis that it is building three pharmaceutical plants in India. It broke ground on a pilot plant and an active pharmaceutical ingredient (API) plant at the company's existing API facility at Alathur, in southern...

  • Actavis Expands into New Markets; May Enter Biosimilars. Ramesh, Deepti // Chemical Week;10/26/2009, Vol. 171 Issue 26, p31 

    The article reports on the decision of generic pharmaceuticals producer Actavis to expand its operations in other regions. According to Stefan Sveinsson, executive vice president of Actavis, the company is planning to enter the biosimilars market through joint ventures and partnerships....

  • Fast-rising generics producer breaks ice in the US via merger. Jarvis, Lisa // Chemical Market Reporter;5/30/2005, Vol. 267 Issue 22, p35 

    Reports that Actavis Group based in Reykjavik, Iceland, has improved its financial performance by making good on a long-standing goal of penetrating the U.S. market in the generic pharmaceuticals arena. Total revenue of the company in 2004; Number of products sold in the U.S. market for...

  • Actavis Acquires Chinese Manufacturer. Ramesh, Deepti // Chemical Week;4/14/2008, Vol. 170 Issue 12, p33 

    The article focuses on the confirmation made by Generics pharmaceutical manufacturer Actavis of Hafnarfjordur, Iceland that it has acquired 90 percent of active pharmaceutical ingredient (API) producer Zhejiang Chiral Medicine Chemicals Co. of Hangzhou, China. Terms of the deal were not...

  • Established Presence.  // Retail Merchandiser;Nov/Dec2009, Vol. 49 Issue 6, p128 

    The article explores how Actavis Group, a generic pharmaceutical manufacturer successfully entered the U.S. market and established Actavis Inc. The company is ranked fifth in terms of size among the world's generic pharmaceutical manufacturers. It relates how Actavis' acquisitions of Amide...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics